Please assess the completion status of the following clinical trial:

Trial Title: Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Superficial TCC: Any G3 or any T1 and/or CIS~* Multifocal (\>1) Ta lesions~* Multiple recurrences (\>2) of Ta lesions in the last 24 months~* Complete tumor eradication must be confirmed~* WHO performance status 0-2 (Appendix V)~* Life expectancy of more than 24 months~* Patients willing to sign informed consent~Exclusion Criteria:~* Bladder tumors other than TCC~* Coexistence of another primary malignant tumor other than BCC of the skin~* TCC of the bladder involving the urethra or upper urinary tract~* Previous history of TCC stage T2 or higher~* Clinical presence or previous history of regional spreading or distant metastases~* Intravesical MMC treatments during the last 12 months~* Previous intravesical BCG therapy (Any intravesical BCG therapy in the last 24 months, or More than 6 BCG intravesical instillations in the last 48 months.~* Previous pelvic radiotherapy or systemic chemotherapy~* Partial cystectomy~* Diverticle of bladder larger than 1cm in diameter~* Residual urine \> 100cc measured by uroflowmetry~* Bladder volume \< 150cc measured by ultrasound~* Urinary incontinence (more than one wet pad a day)~* Urethral stricture impeding 20F catheterization~* Urethral bleeding or persistent hematuria~* Active intractable or uncontrollable UTI~* Active tuberculosis or BCG infection~* Patients who experienced BCG life threatening sepsis~* Known allergy to MMC or BCG~* Known impaired immune response, positive HIV serology, patients receiving systemic steroids or immunosuppressive therapy~* Hematological disorders; leukocytes \< 3500, platelets \< 100,000~* Kidney or liver function disorders (more than 1.5 times upper normal limit)~* Pregnant or lactating women~* Patients who cannot be followed up properly or are unable to collaborate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Synergo + MMC (Type: EXPERIMENTAL): Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
- Bacillus Calmette-Guérin (Type: ACTIVE_COMPARATOR): Intravesical instillation with BCG (Bacillus Calmette-Guérin)

Based on this trial design, predict the completion outcome and termination type (if applicable).